1-[3-[[(3R,7R,9S,10S,12S,13R,14S,17R)-3,7-bis(3-guanidinopropoxy)-10,13-dimethyl-17-[(1R)-1-methyl-4-(octylamino)butyl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-12-yl]oxy]propyl]guanidine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 1-[3-[[(3R,7R,9S,10S,12S,13R,14S,17R)-3,7-bis(3-guanidinopropoxy)-10,13-dimethyl-17-[(1R)-1-methyl-4-(octylamino)butyl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-12-yl]oxy]propyl]guanidine
• 英文别名: 2-[3-[[(3R,7R,9S,10S,12S,13R,14S,17R)-3,7-bis[3-(diaminomethylideneamino)propoxy]-10,13-dimethyl-17-[(2R)-5-(octylamino)pentan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-12-yl]oxy]propyl]guanidine
• 化学式: C₄₄H₈₆N₁₀O₃
• 分子量: 803.2
• InChiKey: DFPUUFRLTBTPMS-DISYNXKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  57
• 可旋转键数：
  27
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  233
• 氢给体数：
  7
• 氢受体数：
  7

文献信息

• MEDICAL DEVICES INCORPORATING CERAGENIN-CONTAINING COMPOSITES
  申请人：Savage Paul B.

  公开号：US20130245760A1

  公开（公告）日：2013-09-19

  A medical device that includes a coating of a composite material that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 μm, 50 nm to 10 μm, 100 nm to 5 Ξm, or 1 μm to 10 μm. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.
• INCORPORATION OF PARTICULATE CERAGENINS IN POLYMERS
  申请人：Savage Paul B.

  公开号：US20130243840A1

  公开（公告）日：2013-09-19

  A composite that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 μm, 50 nm to 10 μm, 100 nm to 5 μm, or 1 μm to 10 μm. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time.
• US20140271761A1
  申请人：——

  公开号：US20140271761A1

  公开（公告）日：2014-09-18
• NOVEL ENDOTRACHEAL TUBE FOR THE REDUCTION OF INTUBATION-RELATED COMPLICATION IN NEONATES AND BABIES
  申请人：Brigham Young University

  公开号：US20170080128A1

  公开（公告）日：2017-03-23

  This disclosure relates to medical devices incorporating one or more cationic steroidal antimicrobials (CSAs). The CSAs are incorporated into the medical devices to provide effective antimicrobial, anti-inflammatory, and/or tissue-healing properties. A medical device includes a component formed from a polymeric material. One or more CSA compounds are mixed with the polymeric material so that the one or more CSA compounds are incorporated into the structure of the medical device as formed from the polymeric material. A medical device can additionally or alternatively include a lubricious coating containing one or more CSA compounds.
• Method of Treating Ciliated Tissue Using CSA Micelles
  申请人：Genberg Carl

  公开号：US20210361672A1

  公开（公告）日：2021-11-25

  The present disclosure describes compositions and methods for preventing and/or treating microbial infections of ciliated tissues, such as tissues of the trachea, lungs, and sinuses. A treatment composition comprises a CSA compound, a poloxamer, and a carrier. The combination of CSA compound and poloxamer allows higher concentrations of CSA compound to be used. Where such doses would normally disrupt ciliary function, the poloxamer prevents damage to ciliated tissue without inhibiting the antimicrobial effectiveness of the CSA compound.